Jefferies lowered its price target on Express Scripts (NASDAQ: ESRX) to $67.00 (from $88.00) while maintaining a Buy rating.

Analyst Brian Tanquilut raises FY 2017 EPS estimate from $1.32 to $1.33 and comments on Anthem (NYSE: ANTM) development: "we are maintaining our Buy rating given our view that the ANTM exit was already partly baked into the stock, and the elimination of the ANTM overhang will enable ESRX to trade at a more appropriate valuation (i.e., 12.7x FY18 P/E) going forward."